|
|
Profile
|
Delegates :
Pohsing Ng |
|
Incorporated :
December 27 , 2016 |
Paid in Capital :
Million yen |
Employees :
人 |
Address :
Ueno Bldg. 8F 1-9-10 Nihonbashi horidomecho, Chuo-ku TOKYO
〒103-0012
|
TEL/FAX :
+81-03-6661-2364 / |
URL：
https://www.hanavax.co.jp/en/ |
Attachment :
 flyer_EN.pdf [ 522.5KiB ] |
Mission/Background :
HanaVax Inc. is developing novel nasal vaccine for healthier society.
In view of COVID-19 worldwide pandemic, we fully realize that to prevent infectious diseases is critically important for not only to protect individual from diseases but to minimize economic and social impact.
Based on many years of research of mucosal immunology, we are developing novel nasal vaccine which prevent not only onset of illness but pathogen invasion and host-to-host transmission.
|
|
Technology & Business
|
Different from most existing vaccines, HanaVax’s vaccine is needle free and is designed as nasal administration.
Therefore HanaVax’s vaccine can induce mucosal immunity at mucosal surface, which can not be accomplished by existing vaccines.
Mucosal immunity induced by nasal vaccine prevent not only onset of illness but pathogen invasion and host-to-host transmission.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
RSV vaccine / Non-typeable Haemophilus influenzae (NTHi) vaccine
|
Preclinical
|
|
IND
|
HPV therapeutic vaccine
|
Preclinical
|
|
|
influenza virus vaccine
|
Discovery
|
|
|
SARS-Cov-2 vaccine
|
Discovery
|
|
|
Mycobacterium tuberculosis vaccine
|
Discovery
|
|
|
|
Highlights
|
Our pipelines include HPV therapeutic vaccine, HSV vaccine, Non-typeable Haemophilus influenzae (NTHi) vaccine, RSV vaccine and TB vaccine. Most of the listed pipelines are candidate for unmet needs medicine and having potential to become blockbuster (>1B USD).
|
|
Alliance strategy
|
1. Out-license partnering with pharma/vaccine manufacturer
2. Partnering with CDMO for manufacturing of biologics (vaccine)
|
|
|